Potential Glioblastoma Therapy with Cationic Cyclodextrin Polymers as Drug Delivery Excipients
Glioblastoma (GB) is the most common and aggressive malignant brain tumor, with a median survival of only 12–15 months despite
A forum for researchers, students and applicants in the field of cyclodextrin technology
Glioblastoma (GB) is the most common and aggressive malignant brain tumor, with a median survival of only 12–15 months despite
Novel cyclodextrin derivatives, such as polyrotaxanes, cyclodextrin-polymer conjugates, and thiolated cyclodextrins, are among the most promising candidates in drug delivery.
The usual thinking with cyclodextrin is about its capacity to complex small molecules, even there is a considerable bibliography about
As the search for energy increases, the drilling depth has increased dramatically due to the progress of drilling technologies over
Removing cationic and zwitterionic compounds extends DEXSORB®’s value proposition to treat polyfluorinated alkyl substances (PFAS) in drinking water The superior